Mesmor

Itraconazole, the active ingredient in Mesmor, is an azole antifungal presented as an intravenous solution for intravenous use. It treats invasive fungal infections such as aspergillosis, candidemia and other systemic mycoses in immunocompromised patients.

GNH USA supplies Mesmor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mesmor, an azole antifungal, is employed to manage serious systemic fungal infections.

- Invasive aspergillosis: effective treatment of life‑threatening lung infection in immunocompromised patients. - Candidemia: eradicates bloodstream Candida infections resistant to other agents. - Blastomycosis: resolves disseminated disease caused by Blastomyces dermatitidis. - Histoplasmosis: clears systemic infection from Histoplasma capsulatum. - Sporotrichosis: treats severe cutaneous and disseminated forms of Sporothrix infection.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes during therapy. - Headache: transient and usually resolves. - Elevated liver enzymes: mild transaminase increase. - Rash: skin irritation or mild erythema. - Fever: low‑grade temperature rise.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Anaphylaxis: acute allergic reaction with airway compromise. - Cardiac failure: worsening of pre‑existing heart conditions. - Visual disturbances: blurred vision or photophobia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Arrhythmias: irregular heart rhythm in susceptible patients.

Mesmor requires careful clinical assessment before and during therapy.

- Renal function: evaluate baseline and monitor during treatment. - Hepatic function: check liver enzymes before initiation and periodically. - Drug interactions: review all concomitant medications for CYP3A4 effects. - Pregnancy and lactation: avoid unless benefits clearly outweigh potential risks. - Cardiac status: contraindicated in patients with uncontrolled heart failure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Itraconazole has notable interactions that may affect safety or efficacy.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that markedly reduces itraconazole levels. - Ketoconazole: additive hepatotoxic risk when combined. - Ergot derivatives: increased risk of ergotism due to CYP3A4 inhibition.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., clarithromycin): may raise itraconazole concentrations. - CYP3A4 inducers (e.g., carbamazepine): may lower drug exposure, reducing effectiveness.